Dyne Therapeutics, Inc. announces the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share, expected to raise $350.0 million. The offering will close on or about December 11, 2025, with an option for underwriters to purchase additional shares. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering. The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC. Dyne Therapeutics focuses on delivering functional improvement for people with neuromuscular diseases through targeted therapeutics for muscle and the central nervous system.

The offering is being made only through a prospectus supplement and accompanying prospectus, available on the SEC’s website. This press release does not constitute an offer to sell securities. Forward-Looking Statements in the press release contain substantial risks and uncertainties. All forward-looking statements, including those related to the anticipated closing date of the public offering, are subject to factors like customary closing conditions and risks discussed in filings with the SEC. Dyne Therapeutics may update forward-looking statements in the future but disclaims any obligation to do so. Contacts for investors: Mia Tobias at [email protected] or 781-317-0353, and for media: Stacy Nartker at [email protected] or 781-317-1938.

Read more at GlobeNewswire: Dyne Therapeutics Announces Pricing of Upsized $350.0